Cargando…

Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing

Lung cancer is the most common cause of cancer-related deaths. Lung cancers can be classified as small-cell (SCLC) or non-small cell (NSCLC). About 84% of all lung cancers are NSCLC and about 16% are SCLC. For the past few years, there have been a lot of new advances in the management of NSCLC in te...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajasegaran, Thiviyadarshini, How, Chee Wun, Saud, Anoosha, Ali, Azhar, Lim, Jonathan Chee Woei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051080/
https://www.ncbi.nlm.nih.gov/pubmed/36986550
http://dx.doi.org/10.3390/ph16030451
_version_ 1785014787938189312
author Rajasegaran, Thiviyadarshini
How, Chee Wun
Saud, Anoosha
Ali, Azhar
Lim, Jonathan Chee Woei
author_facet Rajasegaran, Thiviyadarshini
How, Chee Wun
Saud, Anoosha
Ali, Azhar
Lim, Jonathan Chee Woei
author_sort Rajasegaran, Thiviyadarshini
collection PubMed
description Lung cancer is the most common cause of cancer-related deaths. Lung cancers can be classified as small-cell (SCLC) or non-small cell (NSCLC). About 84% of all lung cancers are NSCLC and about 16% are SCLC. For the past few years, there have been a lot of new advances in the management of NSCLC in terms of screening, diagnosis and treatment. Unfortunately, most of the NSCLCs are resistant to current treatments and eventually progress to advanced stages. In this perspective, we discuss some of the drugs that can be repurposed to specifically target the inflammatory pathway of NSCLC utilizing its well-defined inflammatory tumor microenvironment. Continuous inflammatory conditions are responsible to induce DNA damage and enhance cell division rate in lung tissues. There are existing anti-inflammatory drugs which were found suitable for repurposing in non-small cell lung carcinoma (NSCLC) treatment and drug modification for delivery via inhalation. Repurposing anti-inflammatory drugs and their delivery through the airway is a promising strategy to treat NSCLC. In this review, suitable drug candidates that can be repurposed to treat inflammation-mediated NSCLC will be comprehensively discussed together with their administration via inhalation from physico-chemical and nanocarrier perspectives.
format Online
Article
Text
id pubmed-10051080
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100510802023-03-30 Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing Rajasegaran, Thiviyadarshini How, Chee Wun Saud, Anoosha Ali, Azhar Lim, Jonathan Chee Woei Pharmaceuticals (Basel) Review Lung cancer is the most common cause of cancer-related deaths. Lung cancers can be classified as small-cell (SCLC) or non-small cell (NSCLC). About 84% of all lung cancers are NSCLC and about 16% are SCLC. For the past few years, there have been a lot of new advances in the management of NSCLC in terms of screening, diagnosis and treatment. Unfortunately, most of the NSCLCs are resistant to current treatments and eventually progress to advanced stages. In this perspective, we discuss some of the drugs that can be repurposed to specifically target the inflammatory pathway of NSCLC utilizing its well-defined inflammatory tumor microenvironment. Continuous inflammatory conditions are responsible to induce DNA damage and enhance cell division rate in lung tissues. There are existing anti-inflammatory drugs which were found suitable for repurposing in non-small cell lung carcinoma (NSCLC) treatment and drug modification for delivery via inhalation. Repurposing anti-inflammatory drugs and their delivery through the airway is a promising strategy to treat NSCLC. In this review, suitable drug candidates that can be repurposed to treat inflammation-mediated NSCLC will be comprehensively discussed together with their administration via inhalation from physico-chemical and nanocarrier perspectives. MDPI 2023-03-16 /pmc/articles/PMC10051080/ /pubmed/36986550 http://dx.doi.org/10.3390/ph16030451 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Rajasegaran, Thiviyadarshini
How, Chee Wun
Saud, Anoosha
Ali, Azhar
Lim, Jonathan Chee Woei
Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing
title Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing
title_full Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing
title_fullStr Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing
title_full_unstemmed Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing
title_short Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing
title_sort targeting inflammation in non-small cell lung cancer through drug repurposing
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051080/
https://www.ncbi.nlm.nih.gov/pubmed/36986550
http://dx.doi.org/10.3390/ph16030451
work_keys_str_mv AT rajasegaranthiviyadarshini targetinginflammationinnonsmallcelllungcancerthroughdrugrepurposing
AT howcheewun targetinginflammationinnonsmallcelllungcancerthroughdrugrepurposing
AT saudanoosha targetinginflammationinnonsmallcelllungcancerthroughdrugrepurposing
AT aliazhar targetinginflammationinnonsmallcelllungcancerthroughdrugrepurposing
AT limjonathancheewoei targetinginflammationinnonsmallcelllungcancerthroughdrugrepurposing